Pretreatment with a Single, Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter

• Published in: The journal of clinical endocrinology and metabolism Vol. 88; no. 7; pp. 3121 - 3129
• Main Authors: Nieuwlaat, Willy-Anne, Huysmans, Dyde A., van den Bosch, Harrie C., Sweep, C. G. (Fred), Ross, H. Alec, Corstens, Frans H., Hermus, Ad R.
• Format: Journal Article
• Language: English
• Published: Bethesda, MD Endocrine Society 01-07-2003; Copyright by The Endocrine Society
• Subjects: Aged; Biological and medical sciences; Combined Modality Therapy; Endocrinopathies; Female; Follow-Up Studies; Goiter, Nodular - diagnostic imaging; Goiter, Nodular - drug therapy; Goiter, Nodular - pathology; Hormones. Endocrine system; Humans; Iodine Radioisotopes - pharmacokinetics; Iodine Radioisotopes - therapeutic use; Magnetic Resonance Imaging; Male; Medical sciences; Middle Aged; Non tumoral diseases. Target tissue resistance. Benign neoplasms; Pharmacology. Drug treatments; Radiation Dosage; Radionuclide Imaging; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Thyroid Gland - pathology; Thyroid. Thyroid axis (diseases); Thyrotropin - administration & dosage; Thyrotropin - adverse effects; Endocrinopathy; Human; Nodular goiter; Treatment efficiency; Thyroid diseases; Single dose; Thyroid stimulating hormone; Radioisotope; Glycoprotein hormone; Chemotherapy; Adult; Hormone replacement therapy; Effective dose; Recombinant protein; Pretreatment; Elderly; Iodine
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2002-021554

In patients with nodular goiter, radioiodine (131I) therapy results in a mean reduction in thyroid volume (TV) of approximately 40% after 1 yr. We have demonstrated that pretreatment with a single, low dose of recombinant human TSH (rhTSH) doubles 24-h radioactive iodine uptake (RAIU) in these patients. We have now studied the safety and efficacy of therapy with a reduced dose of 131I after pretreatment with rhTSH.
Twenty-two patients with nodular goiter received 131I therapy, 24 h after im administration of 0.01 (n = 12) or 0.03 (n = 10) mg rhTSH. In preceding diagnostic studies using tracer doses of 131I, 24-h RAIU without and with rhTSH pretreatment (either 0.01 or 0.03 mg) were compared. Therapeutic doses of 131I were adjusted to the rhTSH-induced increases in 24-h RAIU and were aimed at 100 μCi/g thyroid tissue retained at 24 h. Pretreatment with rhTSH allowed dose reduction of 131I therapy by a factor of 1.9 ± 0.5 in the 0.01-mg and by a factor of 2.4 ± 0.4 in the 0.03-mg rhTSH group (P < 0.05, 0.01 vs. 0.03 mg rhTSH). Before and 1 yr after therapy, TV and the smallest cross-sectional area of the tracheal lumen were measured with magnetic resonance imaging. During the year of follow-up, serum TSH, free T4 (FT4), T3, and TSH receptor antibodies were measured at regular intervals.
TV before therapy was 143 ± 54 ml in the 0.01-mg group and 103 ± 44 ml in the 0.03-mg rhTSH group. One year after treatment, TV reduction was 35 ± 14% (0.01 mg rhTSH) and 41 ± 12% (0.03 mg rhTSH). In both groups, smallest cross-sectional area of the tracheal lumen increased significantly. In the 0.01-mg rhTSH group, serum FT4 rose, after 131I treatment, from 15.8 ± 2.8 to 23.2 ± 4.4 pm. In the 0.03-mg rhTSH group, serum FT4 rose from 15.5 ± 2.5 to 23.5 ± 5.1 pm. Individual peak FT4 levels, reached between 1 and 28 d after 131I treatment, were above the normal range in 12 patients. TSH receptor antibodies were negative in all patients before therapy and became positive in 4 patients. Hyperthyroidism developed in 3 of these 4 patients between 23 and 25 wk after therapy.
In conclusion, in patients with nodular goiter pretreatment with a single, low dose of rhTSH allowed approximately 50–60% reduction of the therapeutic dose of radioiodine without compromising the efficacy of TV reduction.